Conditions: Major Depressive Disorder
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 47
Healthy volunteers: yes

Brief summary:
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect each other in the body. Information about any side effects that may occur will also be collected.

Detailed description:
Clopidogrel is rapidly converted to R-130964 by the enzyme cytochrome P450 2C19 (CYP2C19). Enrollment in the study was limited to participants with specific genotypes of the CYP2C19 gene, including the \*1/\*1 genotype (CYP2C19 extensive metabolizers) and the \*1/\*17 or \*17/\*17 genotypes (CYP2C19 ultra-rapid metabolizers). All primary and secondary objectives were limited to participants with the CYP2C19\*1/\*1 genotype.

Arms:
arm 1: Period 1: a single 300-milligram (mg) dose of clopidogrel administered orally on Day 1 (Treatment 1).

Period 2: an 18-mg dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).

There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2. arm 2: Period 1: an 18-milligram (mg) dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).

Period 2: a single 300-mg dose of clopidogrel administered orally on Day 1 (Treatment 1).

There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2.

Interventions: intervention 1: Clopidogrel intervention 2: LY2216684
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: